Skip to search formSkip to main contentSkip to account menu

FR 901228

Known as: Antibiotic FR 901228, FR-901228, FR901228 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
Depsipeptide is in clinical trials for chronic lymphocytic leukemia (CLL) on the basis of earlier observations demonstrating… 
Review
2003
Review
2003
The potential anticancer activities of histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors have… 
Highly Cited
2002
Highly Cited
2002
By preventing deacetylation of histones, histone deacetylase inhibitors (HDIs) transcriptionally induce p21. Here we show that… 
Highly Cited
2002
Highly Cited
2002
Depsipeptide (FR901228) is a bicyclic peptide isolated from Chromobacterium violaceum that has demonstrated potent in vitro… 
Highly Cited
2001
Highly Cited
2001
Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines… 
Review
2001
Review
2001
Abstract. Trichostatin A (TSA) and trapoxin (TPX), inhibitors of the eukaryotic cell cycle and inducers of morphological… 
Highly Cited
2000
Highly Cited
2000
Depsipeptide, FR901228, a novel cyclic peptide inhibitor of histone deacetylase with a unique cytotoxicity profile is currently… 
Highly Cited
1998
Highly Cited
1998
Screening for microbial metabolites that induce transcriptional activation of the SV40 promoter resulted in the identification of… 
Highly Cited
1994
Highly Cited
1994
A novel antitumor bicyclic depsipeptide, FR901228, was isolated from a broth culture of Chromobacterium violaceum No. 968 as… 
Highly Cited
1994
Highly Cited
1994
FR901228, a novel antitumor antibiotic, reversed the transformed morphology of the Ha-ras transformants, Ras-1 cells, and…